FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

Documenti analoghi

• FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
  di: Couillard, S, et al.
  Pubblicazione: (2021)
• Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
  di: Couillard, S, et al.
  Pubblicazione: (2020)
• Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma
  di: Khalfaoui, L, et al.
  Pubblicazione: (2022)
• Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework
  di: Couillard, S, et al.
  Pubblicazione: (2022)
• Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
  di: Couillard, S, et al.
  Pubblicazione: (2022)